Du Ying, Chairperson & CEO, has demonstrated a pronounced selling bias in their recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 32 transactions, all involving Zai Lab Limited (ZLAB), Du Ying has sold shares totaling $21,643,870.51, compared to purchases amounting to $1,645,383.48. Notably, the most recent transactions, spanning March 2026, have been exclusively sales, with nine sell transactions recorded. These include significant sales on March 11 ($20,362.63), March 9 ($951,465), March 6 ($970,935), March 5 ($961,055), and March 4 ($689,831.50 and $268,321.90). Earlier transactions in August 2025 also reflect a consistent pattern of selling, with notable sales on August 13 ($1,645,286.59), August 12 ($1,712,555), and August 11 ($1,731,815).
The transactions also include exercises of derivative securities, such as options, which are often associated with the acquisition of shares, but these have been accompanied by immediate sales. For example, on March 10, 2026, Du Ying exercised options with a value of $2,269,727.76 and $454,300.08, followed by sales. Similarly, on August 29, 2025, options worth $8,190,486.21 were exercised, with subsequent sales. This pattern suggests that Du Ying has been consistently liquidating holdings in ZLAB, with no recent purchases to offset the sales. The data underscores a clear trend of divestment in ZLAB shares over the observed period.
AI-assisted summary